振德醫療(603301.SH):不提前贖回“振德轉債”
格隆匯 7 月 17日丨振德醫療(603301.SH)公佈,2020年7月17日,公司召開第二屆董事會第八次會議,審議通過了《關於不提前贖回“振德轉債”的議案》,因“振德轉債”進入轉股期時間較短,相關募集資金已有支出安排,擬用於募投項目建設等生產經營活動,公司董事會結合當前市場情況及公司綜合考慮,決定本次不行使“振德轉債”的提前贖回權利,不提前贖回“振德轉債”。
截至2020年7月17日收盤,公司股票價格為74.18元/股,“振德轉債”當期轉股價為14.01元/股。根據振德轉債募集説明書的相關規定,後續“振德轉債”可能再次觸發贖回條款,屆時公司董事會將再次召開會議決定是否行使“振德轉債”的提前贖回權利。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.